» Articles » PMID: 24295985

In Vitro and in Vivo Antibacterial Activities of Omadacycline, a Novel Aminomethylcycline

Overview
Specialty Pharmacology
Date 2013 Dec 4
PMID 24295985
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Omadacycline is the first intravenous and oral 9-aminomethylcycline in clinical development for use against multiple infectious diseases including acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). The comparative in vitro activity of omadacycline was determined against a broad panel of Gram-positive clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Lancefield groups A and B beta-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae (PRSP), and Haemophilus influenzae (H. influenzae). The omadacycline MIC90s for MRSA, VRE, and beta-hemolytic streptococci were 1.0 μg/ml, 0.25 μg/ml, and 0.5 μg/ml, respectively, and the omadacycline MIC90s for PRSP and H. influenzae were 0.25 μg/ml and 2.0 μg/ml, respectively. Omadacycline was active against organisms demonstrating the two major mechanisms of resistance, ribosomal protection and active tetracycline efflux. In vivo efficacy of omadacycline was demonstrated using an intraperitoneal infection model in mice. A single intravenous dose of omadacycline exhibited efficacy against Streptococcus pneumoniae, Escherichia coli, and Staphylococcus aureus, including tet(M) and tet(K) efflux-containing strains and MRSA strains. The 50% effective doses (ED50s) for Streptococcus pneumoniae obtained ranged from 0.45 mg/kg to 3.39 mg/kg, the ED50s for Staphylococcus aureus obtained ranged from 0.30 mg/kg to 1.74 mg/kg, and the ED50 for Escherichia coli was 2.02 mg/kg. These results demonstrate potent in vivo efficacy including activity against strains containing common resistance determinants. Omadacycline demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens, including resistance determinant-containing strains, and this activity translated to potent efficacy in vivo.

Citing Articles

New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).

File Jr T, Ramirez J, Wilde A Antimicrob Agents Chemother. 2025; 69(2):e0108724.

PMID: 39817764 PMC: 11823662. DOI: 10.1128/aac.01087-24.


High Rates of Nonsusceptibility to Common Oral Antibiotics in Clinical Isolates From the United States (2019-2021).

Deshpande L, Huband M, Charbon S, Castanheira M, Mendes R Open Forum Infect Dis. 2024; 11(9):ofae470.

PMID: 39229287 PMC: 11370784. DOI: 10.1093/ofid/ofae470.


Zidovudine in synergistic combination with nitrofurantoin or omadacycline: and in murine urinary tract or lung infection evaluation against multidrug-resistant .

Tian P, Li Q, Guo M, Zhu Y, Zhu R, Guo Y Antimicrob Agents Chemother. 2024; 68(10):e0034424.

PMID: 39194261 PMC: 11459972. DOI: 10.1128/aac.00344-24.


Omadacycline is active and against ciprofloxacin-resistant .

Heine H, Drusano G, Purcell B, Anastasiou D, Tanaka S, Serio A Antimicrob Agents Chemother. 2024; 68(9):e0059524.

PMID: 39133023 PMC: 11373220. DOI: 10.1128/aac.00595-24.


Case Report of Severe Pneumonia Treated with Omadacycline.

Chen Y, Tong J, Wang J Int Med Case Rep J. 2024; 17:659-663.

PMID: 38978986 PMC: 11230114. DOI: 10.2147/IMCRJ.S473469.


References
1.
Cai Y, Wang R, Liang B, Bai N, Liu Y . Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2010; 55(3):1162-72. PMC: 3067123. DOI: 10.1128/AAC.01402-10. View

2.
Noel G, Draper M, Hait H, Tanaka S, Arbeit R . A randomized, evaluator-blind, phase 2 study comparing the safety and efficacy of omadacycline to those of linezolid for treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2012; 56(11):5650-4. PMC: 3486554. DOI: 10.1128/AAC.00948-12. View

3.
Ng L, Martin I, Alfa M, Mulvey M . Multiplex PCR for the detection of tetracycline resistant genes. Mol Cell Probes. 2001; 15(4):209-15. DOI: 10.1006/mcpr.2001.0363. View

4.
Bradford P, Weaver-Sands D, Petersen P . In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis. 2005; 41 Suppl 5:S315-32. DOI: 10.1086/431673. View

5.
Chopra I . Glycylcyclines: third-generation tetracycline antibiotics. Curr Opin Pharmacol. 2002; 1(5):464-9. DOI: 10.1016/s1471-4892(01)00081-9. View